Clinical Trials Browser

OTHER × Breast Neoplasms × tislelizumab × Clear all

NCT06547476 2024-08-09

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Phase 2 Not yet recruiting

Breast Neoplasms

NCT04734262 2023-11-18

SPARK

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05861635 2023-05-17

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Phase 4 Unknown

Breast Neoplasms